ClinicalTrials.gg
CompletedNCT07575945Updated Aug 21, 2026

A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults.

A Phase 1 interventional study of PF-08642534 and Itraconazole in Healthy Participant, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to learn if a medicine called itraconazole changes how the body processes the study medicine (PF-08642534) in healthy adults.

This study is seeking healthy participants (men or women) who:

  • are aged 18 to 65 years of age
  • are confirmed to be healthy by their medical history and medical tests
  • have body mass index (BMI) of 16 to 30 kilograms per meter squared
  • have a total body weight of more than 50 kilograms.

Participants will receive single doses of the study medicine (PF-08642534) with and without itraconazole.

The total planned time of participation is about 12 weeks. The study consists of:

  • a screening period of up to 28 days before taking study drug
  • about 4 weeks of staying in the study clinic
  • a follow-up contact that will occur 28 to 35 days after taking itraconazole the last time.
02

Conditions studied

  • Healthy Participant
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Generally healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, blood pressure, pulse rate and standard 12-lead (ECG).
  • (BMI) of 16-30 kilograms per meter squared, inclusive, and a total body weight greater than 50 kilograms (110 pounds).

Exclusion criteria

Exclusion criteria:

  • Evidence or history of disease
  • Specified abnormalities in safety assessments at Screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Period 1--PF-08642534

    Participants will receive a single dose of PF-08642534

    Drug: PF-08642534

  • Experimental
    Period 2--itraconazole plus PF-08642534

    Participants will receive single doses of PF-08642534) in presence of itraconazole.

    Drug: PF-08642534 · Drug: Itraconazole

Interventions

  • DrugPF-08642534

    Participants will receive a single dose of PF-08642534

  • Participants will receive itraconazole once daily for 13 days (Day 12 to Day 24)

06

What researchers measure

Primary outcomes

  1. PF-08642534 Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Time frame: 0 to 240 hours post-dose

Secondary outcomes

  1. Incidence of treatment-emergent Adverse Events

    Time frame: Baseline up to approximately 8 weeks

07

Study locations

1 site
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in Jun 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 8, 2026
StartActual
May 5, 2026
Primary completionActual
Jun 26, 2026
CompletionActual
Jul 23, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07575945
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 8, 2026
Start date
May 5, 2026
Primary completion
Jun 26, 2026
Completion
Jul 23, 2026
Last update
Aug 21, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion